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Abstract
Summary This is the first report examining vitamin D status
and bone mass in African women with HIV infection using
dual-energy X-ray absorptiometry (DXA) with an appropriate
HIV-negative control group. Unlike previous publications, it
demonstrates no difference in bone mineral density (BMD) or
vitamin D status in HIV-positive patients, at different disease
stages, vs. HIV-negative subjects.
Introduction Low bone mass and poor vitamin D status
have been reported among HIV-positive patients; suggesting
HIVor its treatment may increase the risk of osteoporosis, a
particular concern for women in countries with high HIV
prevalence such as South Africa. We describe bone mass
and vitamin D status in urban premenopausal South African
women, who were HIV positive but not on antiretroviral
therapy (ARV).
Methods This study is a cross-sectional measurement of
BMD and body composition by DXA and vitamin D status
by serum 25-hydroxyvitamin D (25(OH)D) concentration.
Subjects were recruited into three groups: HIV negative
(n=98) and HIV positive with preserved CD4 cell count
(non-ARV; n=74) or low CD4 cell counts prior to ARVinitiation
(pre-ARV; n=75).
Results The mean (standard deviation (SD)) age of women was
32.1 (7.2) years. Mean CD4 (SD) counts (×10
6/l) were 412 (91)
and 161 (69) in non-ARVand pre-ARV groups (p<0.0001). Pre-
ARVwomenwere significantly lighter and had lowermeanBMI
than the other two groups (p<0.002). The pre-ARV group also
had significantly less fat and lean mass compared with non-ARV
and HIV-negative subjects (p≤0.05). After full adjustment, there
were no significant differences in BMD at any site (p>0.05)
between the groups, nor was vitamin D status significantly
different between groups (p>0.05); the mean (SD) cohort
25(OH)D being 60 (18) nmol/l.
Conclusion Contrary to previous studies, these HIV-positive
women did not have lower BMD or 25(OH)D concentrations
than HIV-negative controls, despite the pre-ARV group being
lighter with lower BMI.
Keywords Body composition . Bone mineral density . Dual
energy X-ray absorptiometry . HIV infection . Vitamin D
Introduction
HIV infection and the use of antiretroviral (ARV) medication
have been associated with low bone mineral density (BMD)
and poor vitamin D status. In a meta-analysis, the prevalence
of low BMD in HIV-positive individuals was three times
higher than in HIV-negative controls [1–3]. Similarly, studies
have described high prevalence of low 25-hydroxyvitamin D
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(25(OH)D) concentrations in HIV-positive patients [4]. Some
studies of the effects of HIV and/or its treatment on bone are
limited by retrospective design, a preponderance of white,
male subjects, and lack of HIV-negative controls [5] while
others are prospective [6] and do include women [7, 8]. Other
studies are limited by confounding by low body weight or
other risk factors for low BMD, such as intravenous drug use
(IDU), exposure to a large variety of ARV regimes and mea-
surement of BMD and vitamin D status after varying duration
of ARVexposure [6]. The few prospective studies focusing on
women have also been limited by some of these aspects [6, 9],
and as a result it is difficult to ascertain with certainty if HIV
infection and/or its treatment or factors unrelated to HIV
infection are contributing factors to the low bone mass and
low vitamin D status described in the current literature. In
contrast, there are data to suggest that after adjusting for body
weight, BMD is normal or near normal, and that patients on
ARV do not have increased rates of bone loss [10, 11]. As a
result, there is not a definitive consensus on the contribution of
HIV infection or ARVexposure on BMD in infected individuals.
In South Africa, estimates of HIV prevalence for 2010 are
10.5% for the total population and 29.3% for women attending
antenatal clinics. The epidemic is described as “hyperendemic”
because of the high prevalence and continuing drivers of trans-
mission [12–14]. In South Africa, individuals generally become
eligible for ARV treatment when their CD4 count is less than a
nationally specified threshold. By 2009, 56% of those requiring
ARVwere able to receive them, with the government intending
to increase ARV coverage to 80 % by 2011 [12].
Vitamin D has well-known associations with bone health
via its role in calcium and phosphate homeostasis, and
vitamin D status is considered an important modulator of
immune function by some authors [14–16]. In South Africa,
adults are largely dependent on the cutaneous synthesis of
vitamin D to maintain vitamin D status, as only small
amounts of vitamin D are obtained from the diet due to
limited food fortification. In Johannesburg (26° S latitude),
there is sufficient ultraviolet B (UVB) radiation in sunshine
throughout the year for dermal synthesis of vitamin D [17].
Nevertheless, vitamin D deficiency has been described in
tropical/subtropical countries despite the potential for ade-
quate skin exposure to UVB-containing sunshine [18].
The aim of the study presented here was to describe
BMD, body composition and vitamin D status in South
African women with and without HIV infection, prior to a
planned longitudinal study of this cohort to chart the
changes in these outcomes over time. We hypothesised that
HIV-positive women with low CD4 counts, below the
threshold that would make them eligible for ARV treatment,
would have lower bone mass, less fat and muscle mass and
inferior vitamin D status than HIV-positive women with




Urban, black, premenopausal, South African women (n=247)
were recruited from clinics in Soweto, Greater Johannesburg
and enrolled into the study between February and July 2010.
Subjects were recruited from a voluntary counselling and
testing clinic and local health clinics. The aim was to recruit
95 HIV-negative and 73 (±10) in each of two HIV-positive
groups (with or without low CD4 counts). This sample size
was based on calculations for the longitudinal study to detect a
2 % change in lumbar spine BMD, allowing for a between-
individual coefficient of variation in BMD of 5 %, with 95 %
confidence and 80 % power. For the study presented here, this
sample size was sufficient for a comparison of three groups to
allow the detection of mean differences between each pair of
groups of around 0.4 standard deviation (SD) at 5 % signifi-
cance and 80 % power. The study was approved by the
University of the Witwatersrand Human Research Ethics
Committee (HREC number: M101525) and the Gauteng
Department of Health.
Eligible subjects were adult females (defined as aged
greater than 18 years) and premenopausal (defined as regu-
lar menses). Other inclusion criteria included a documented
negative HIV test within the last 12 weeks for HIV-negative
women and a documented positive HIV test for all other
women. Patient-retained clinic records were scrutinised
whenever possible to confirm medical history, current CD4
count, prior exposure to ARVs and concurrent medication
use. Exclusion criteria included conditions associated with
abnormal bone metabolism or current use of medication likely
to affect bone or vitamin D status such as bisphosphonates.
Pregnant and lactating women were excluded as were those
with an acute medical condition. The group with the lowest
CD4 count were largely recruited after the other groups: May
to June and February to April, respectively.
Study posters were displayed in the clinic and training
sessions undertaken with clinic staff. Women who expressed
an interest in the study underwent initial telephone screen-
ing, in their language, to ensure inclusion and exclusion
criteria were met. Prior to enrolment, potential subjects
completed a medical- and health-related questionnaire to
assess past and current health status and medication use
and to further assess compliance with inclusion and exclu-
sion criteria. Women who remained eligible were enrolled in
the full study after they had provided written consent.
The enrolled women consisted of HIV-negative (n=98)
and HIV-positive (n=149) subjects. The HIV-positive wom-
en were recruited into two prespecified groups: those with
relatively preserved CD4 counts (>350×10
6 cells/l), not
requiring ARV therapy (non-ARV group; n=74) and those
with low CD4 counts (in the region of 200×10
6 cells/l)
2856 Osteoporos Int (2013) 24:2855–2861
requiring ARV initiation (pre-ARV group; n=75) according
to the current South Africa (SA) treatment guidelines [19].
HIV-negative status was confirmed using the Determine™
rapid HIV-antibody test (Alere San Diego, Inc., San Diego,
CA, USA), while HIV-positive status was established using
a second platform. HIV-positive women were either newly
diagnosed or known to be HIV positive, but not on ARVs.
All HIV-positive women provided an up-to-date (within
3 months) CD4 count prior to enrolling into the study. All
HIV-positive women received SA standard of care with
respect to ARV provision and clinical follow up. Women
requiring urgent ARV initiation were managed in such a way
that there would be no delay in ARV initiation if they were
to participate in the study.
Women attended the Developmental Pathways for Health
Research Unit (DPHRU) facility at the Chris Hani
Baragwanath Academic Hospital, after an overnight fast
and underwent phlebotomy, anthropometry, and dual-
energy X-ray absorptiometry (DXA) assessment of bone
mass and body composition. After phlebotomy, subjects
were given breakfast and each received ZAR 50.00
(≈US$6.25) for travel expenses.
Anthropometry
Height was measured to the nearest millimetre using a
stadiometer (Holtain, Crosswell, UK). Weight was mea-
sured to the nearest 100 g using a digital scale (Tanita,
TBF-410 MA Body Composition Analyzer, Tanita Corpo-
ration of America, Inc., Arlington Heights, IL, USA) with
participants wearing light clothing and no shoes. BMI was
calculated as the participant’s weight in kilograms divided
by the square of their height in metres (in kilogram per
square metre). Underweight, normal, overweight, and obese
were defined as BMI <18.5, 18.5–24.9, 25–29.9,
≥30.0 kg/m2, respectively [20].
Bone absorptiometry and body composition measurements
DXA was performed using a Hologic QDR 4500A DXA
(model: Discovery W (S/N 71201) software version 12.5:7
Hologic, Inc., Waltham, MA, USA) according to standard
procedures. Scans were conducted using the automatic scan
mode, i.e. ‘array’, ‘fast array’ or ‘slow array’, depending on
the weight of the subjects. Subjects wore light clothing
having removed metal objects, jewellery, etc. DXA was
used to measure bone mineral content (BMC, in grams),
bone area (BA, in square centimetre) and areal BMD (in
grams per square centimetre), of whole body (WB), total hip
(TH), femoral neck (FN) and lumbar spine (LS). The co-
efficients of variation (CV%) for repeated measurements of
the manufacturer’s phantom were 0.3, 0.4 and 0.2 % for BA,
BMC and BMD, respectively. The CV for repeated
measurement by the DXA operator of the LS and TH
BMD were 0.7 and 1.0 %, respectively. DXA scans for
WB were analysed using WB less head (WBLH) as
many women wore wigs and hair weaves that could
not be removed prior to scanning. This artificial hair
was of similar density to soft tissue and therefore could
cause measurement artefact. Total fat and lean body mass
(in grams) were also measured by DXA.
Laboratory analysis
Blood was collected for 25(OH)D analysis, measured by
chemi-luminescent immunoassay (Liason) kit (DiaSorin
Inc., Stillwater, MN, USA). The blood samples were
allowed to clot for a minimum of 20 min at room tempera-
ture, and the serum was aliquoted and stored at −20 C until
analysed. All samples were run in duplicate. The inter-assay
CV for low and higher 25(OH)D controls was 10 and 9 %,
respectively, whereas the intra-assay CV was 8 and 6 %,
respectively. The DPHRU laboratory participates in the
International Vitamin D External Quality Assessment
Scheme and holds the certificate of proficiency [21].
Statistical analysis
Data were analysed using DataDesk 6.3.1 (Data Description
Inc, Ithaca, NY, USA) and summary statistics were document-
ed asmean (SD) or median (interquartile range), depending on
the distribution. Comparisons were made between the three
groups of women using hierarchical linear models; ANOVA
(or ANCOVA) and Scheffé post hoc tests were used to
compare group means (standard error (SE)). To consider the
possible influence of group differences in bone and body
size, bone mineral data were adjusted for age, weight,
height and bone area, and bone area was adjusted for age,
weight and height, using ANCOVA [16]. Preliminary plots
of the relationship between fat mass and lean mass in this
sample population demonstrated non-linearity. Regression
of fat mass on lean mass in the HIV-negative control group
with data in natural logarithms gave a power exponent 2.05±
0.18 (SE) , indicating that fat mass-to-lean square mass best
described the relationship in this population. The exponent
was similar when the data from all three groups were included
in the model; 2.07±0.14. Consequently, a fat mass-to-lean
square mass term was used to describe differences in body
composition between the groups, and logarithmic regression
was used to adjust fat mass for lean mass in statistical
models. BMD SD scores (SDS) were generated using
HIV-negative subjects as the reference population (ref)
against which the SDS for each individual HIV-positive
woman (i) was derived as follows: [(BMDi−mean
BMDref)/SDref]. A p value of ≤0.05 was considered to be
statistically significant.
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Results
Subject characteristics
By design, the mean CD4 count (×10
6 cells/l) in the pre-
ARV group was significantly lower than that in the non-ARV
group (412 (91) and 161 (69), respectively, p<0.0001). The
mode of acquisition of HIV-infection was via heterosexual
transmission in all subjects, only one subject reporting IDU in
the past (Table 1).
Mean age (SD) was 32.1 (7.2) years with HIV-negative
women being significantly but only slightly younger than
both groups of HIV-positive women. The age ranges were
similar in the three groups (18–49, 22–48 and 19–47 years
in HIV-negative, non-ARVand pre-ARVwomen, respectively).
Median (IQR) gravidity was 2 (1; 3) with both HIV-positive
groups having a higher median gravidity compared to the HIV-
negative group.
Anthropometry and body composition
HIV-negative women tended to be shorter than both groups
with HIV-infection (p=0.06), while HIV positive, pre-ARV
women were significantly lighter than the other two groups
(p<0.05). Median (IQR) BMI of the study cohort was 26.1
(22.4; 31) kg/m2 with BMI in pre-ARV women being signif-
icantly lower than in HIV-negative and non-ARV women.
Combined overweight and obesity represented 65, 65 and
Table 1 Subject characteristics, anthropometric measurements and vitamin D status as measured by serum 25(OH)D
Group 1 Group 2 Group 3 Group effect
HIV-negative HIV-positive, non-ARV HIV-positive, pre-ARV ANOVA
n=98 n=74 n=75 p
Age (years) 30.0 (8.1) 33.5 (6.1)a 33.4 (6.5)a 0.001
HIV status Negative Positive Positive
Current CD4 count ×10
6 cells/l ND 412 (91) 161 (69)b <0.001
Median (IQR) 420 (127;409) 175 (120;165)
Min NA 240 18
Max NA 604 275
Gravidity median (IQR) 1 (0;2) 2 (2;3)a 2 (1;3)a
Range 0–5 0–6 0–6
Current hormonal contraceptive use (%) 34 (35.4) 26 (36.6) 25 (33.3) 0.9
Current smoking (%) 10.2 13.5 8 0.2
Height (cm) 157.6 (5.9) 159.4 (5.9) 159.2 (5.3) 0.06
Weight (kg) 69.7 (17.0) 72.0 (17.4) 62.3 (15.2)c,d <0.001
BMI (kg/m2) Median (IQR) 27.3 (23.1;31.7) 27.8 (23.3;32.3) 23.5 (20.5;27.0)d,e <0.001
Overweight BMI >24.9 kg/m2, <30 kg/m2 (%) 35 28 28
Obese BMI >30 kg/m2 (%) 30 37 16
Underweight BMI <18.5 kg/m2 (%) 4 1 11
WBLH Fat (kg) 26.1 (11.5) 26.1 (9.8) 19.7 (9.3)b,e <0.0001
WBLH Lean (kg) 38.3 (60.8) 39.5 (62.4) 36.4 (48.1)d 0.005
Fat/lean2 (kg/kg2)* 17.32 (4.80) 15.92 (4.56) 14.58 (5.47)a,f 0.002
25(OH)D (nmol/l) 59.7 (16.5) 59.2 (16.5) 61.6 (22.3) 0.7
25(OH)D (nmol/l) >50 (%) 73.5 70.3 66.7
25(OH)D (nmol/l) <50 (%) 26.5 29.7 33.3
25(OH)D (nmol/l) <25 (%) 1.0 2.7 5.3
All values are mean (SD) unless indicated. Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffé
25(OH)D 25 hydroxyvitamin D, ARV antiretroviral therapy, cm centimetres, IQR interquartile range, kg kilograms, SD standard deviation, WBLH
whole body less head, ND not determined, NA not applicable
*Value multiplied by 1,000 to illustrate the relative differences in kilogram
a Significantly different from group 1, p≤0.01
b Significantly different from group 2, p≤0.001
c Significantly different from group 1, p≤0.05
d Significantly different from group 2, p≤0.01
e Significantly different from group 1, p≤0.001
f Significantly different from group 2, p≤0.05
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44 % of subjects in HIV-negative, non-ARV and pre-ARV
women, respectively , while underweight was present in 4, 1
and 11 %, respectively (Table 1).
There were significant differences in fat mass between
groups with pre-ARV women having significantly lower fat
mass than non-ARV women (p≤0.001). Although lean mass
was also lower in pre-ARV compared with non-ARV women
(p=0.005) the pre-ARV group had lower fat mass-to-lean
square mass ratio than the other two groups (p=0.002). When
fully adjusting for lean mass using logarithmic regression, the
pre-ARV group had significantly lower fat mass for their lean
mass than the other two groups; such that for each unit of lean
mass the pre-ARV group had a mean difference (SE) of 21
(5)% less fat than the controls, p=0.0002, and 16 (5)% less fat
than the non-ARV group, p=0.02.
Bone measures
No significant differences in BMD at the TH, FN, LS and
WBLH were found, and age and size adjustment did not
reveal any differences between groups. When expressed as
SD scores, there were no significant differences between
pre-ARVand non-ARV groups in BMD for any site measured
(p>0.05) and all the mean values were within a −0.5 SD of the
HIV-negative reference group (Table 2). In addition, no signif-
icant differences were found in BMC values except at WBLH
when fully adjusted for age, size and BA (p=0.03). Unadjusted
BA was significantly greater in both groups of HIV-positive
women than HIV-negative women at some sites but these dif-
ferences disappeared after adjusting for age and size (see Elec-
tronic supplementary material (ESM) for BA and BMC data).
Vitamin D status
Mean (SD) 25(OH)D for the whole cohort was 60.1 (18.4)
nmol/l and there were no significant differences between
groups (p>0.05). 25(OH)D concentration was <50 nmol/l in
29.6 % of individuals; with similar proportions in each of the
groups in this category (26.5, 29.7 and 33.3 % in HIV-
negative, non-ARV and pre-ARV, respectively). Very few
subjects had a 25(OH)D concentration <25 nmol/l (1.0, 2.7
and 5.3 % in the three groups, respectively), despite the
slightly greater number of pre-ARV subjects whose blood
samples for 25(OH)D measurement were obtained during
the winter months.
Discussion
The aim of this study was to determine whether South African
HIV-positive women with preserved CD4 counts differed from
those with low CD4 counts making them eligible for ARVand
to compare each group with HIV-negative women. In this
group of urban, South African women, pre-ARV women were
significantly lighter than HIV-negative and non-ARV subjects
and had lower fat mass than expected for their lean mass,
raising the possibility that women with advancing HIV disease
preferentially lose fat rather than lean mass. There were no
significant differences between groups in BMC or BMD at any
site before or after adjustment for age, BA, weight and height
and the observed smaller BA in the HIV-negative women
disappeared after adjustment for age, height and weight. There
was no significant difference in vitamin D status between
groups with the majority of subjects having a serum concen-
tration >50 nmol/l.
The assessment of ‘optimal’ vitamin D status is problematic
because varying cut offs are used to define sufficiency, insuf-
ficiency and deficiency [22]. A concentration below 25 nmol/l
is generally recognised as indicating an increased risk of rickets
and osteomalacia [23]. The 2010 Institute of Medicine report
considered that a blood 25(OH)D concentration of 20 ng/mL
(50 nmol/l) to be sufficient for good bone health in ‘practically
all individuals’ [24]. However, it noted that evidence was
lacking to make a similar statement regarding non-skeletal
health. In the context of HIV infection and ARV use, the
optimal vitamin D status remains undefined because there
Table 2 BMD of the three groups of South African women
BMD (g/cm2) Group effecta
Mean (SD) p
Group 1 Group 2 Group 3
HIV-negative HIV-positive, non-ARV HIV-positive, pre-ARV
n=98 n=74 n=75
Total Hip 1.013 (0.131) 0.985 (0.124) 0.988 (0.125) 0.3
Femoral Neck 0.930 (0.114) 0.916 (0.125) 0.923 (0.131) 0.8
Lumbar Spine 1.018 (0.118) 1.021 (0.109) 1.006 (0.128) 0.7
WBLH 0.958 (0.079) 0.943 (0.071) 0.947 (0.080) 0.4
ARV antiretroviral therapy, BMD bone mineral density (in gram per square centimetre), SD standard deviation, WBLH whole body less head
a Group effect by ANOVA. There were no significant differences between pairs of groups by Scheffé post hoc tests
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may be different requirements for maximal bone health and
immune functioning compared with HIV-negative
populations. However, in contrast to other reports [4, 25], in
our study, there were no indications that HIV infection was
associated with inferior vitamin D status because there were no
significant differences in vitamin D status between the three
groups, the distributions of 25(OH)D concentration were sim-
ilar, and vitamin D status appeared to be generally adequate
with very few women having a concentration <25 nmol/l.
Contrary to previous reports [9], we found no significant
differences in BMD between either group of HIV-positive
and HIV-negative women. Full adjustment for bone and
body size did not alter these results. This lack of any
differences is surprising as HIV-positive women with low
CD4 counts, requiring ARV initiation, were significantly
lighter, with lower fat and lean mass, than the other women.
However, it may reflect the selection criteria for this study
because despite recruiting women with low CD4 counts, of
clinical concern, women with severe clinical disease re-
ceived immediate ARV therapy and were thus excluded
from the study. It may also be influenced by the fact that
the subjects were not intravenous drug users and thus not
exposed to the additional effect on BMD that this poses.
Another limitation may be that the groups were different in
terms of duration of hormonal contraception use, parity and
total duration of lactation; however, at the time of the study,
no women were pregnant or lactating. The findings are also
limited by the fact that the sample of HIV-positive women
was likely to be heterogeneous with respect to immune
status and duration of infection. However, most other stud-
ies have also recruited HIV-positive subjects in a similar
manner and this is unlikely to account for the different
findings in our study.
The rates of combined overweight and obesity 65% in HIV-
negative and non-ARV subjects in this study were greater than
the national average in South Africa of 51.5 % [26]; even
women with advanced HIV-disease (pre-ARV group) had a
combined overweight and obesity rate of 44 %. It is possible,
therefore, that the typically high weight of South African wom-
en has a sparing effect on bone in those with HIV infection,
evenwith CD4 counts below the threshold for initiation of ARV
intervention.
Historically, being overweight has been viewed as protective
against osteoporotic fracture, although evidence is emerging
that overweight and obesity may be a risk factor for leg fragility
fractures in women [27]. In the study population of younger
black women in South Africa, there were no significant differ-
ences in BMDSD score, expressed relative to the HIV-negative
group, according to HIV status at any site. The effects of HIV
and its treatment on fracture risk in South Africa are unknown.
The lack of difference between the groups which is at
variance from previously reported studies may be the result
of true lack of effect of HIV infection or reflect important
differences in bone response to HIV between black Africans
and Caucasians. The study design in which two distinct
groups of HIV-positive women, based on South African
eligibility criteria for ARV treatment plus the inclusion of
a HIV-negative control group strengthens the finding that
HIV infection with varying degree of immunosuppression
does not appear to be driving alterations in BMD or vitamin
D status in these young, urban women. The high rates of
overweight may be masking more dramatic differences in
BMD and vitamin D in those subjects with advanced clin-
ical HIV disease not included in this study. Further work is
required to address the effects of ARVexposure on bone and
vitamin D status as well as the relative effect of ‘traditional’
osteoporosis risk factors in this population. The data from
this study provide an insight into bone health, body com-
position and vitamin D status in African women living
with HIV. They challenge our own hypotheses and previ-
ously reported differences in BMD and vitamin D status
in HIV-positive subjects living in developed countries and
highlight the importance of studying subjects prior to
ARV exposure.
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